| # | Title | Journal | Year | Citations |
|---|
| 1 | PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy | Molecular Cancer Therapeutics | 2015 | 1,787 |
| 2 | Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers | Molecular Cancer Therapeutics | 2017 | 1,779 |
| 3 | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling | Molecular Cancer Therapeutics | 2008 | 1,237 |
| 4 | Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Molecular Cancer Therapeutics | 2008 | 1,095 |
| 5 | Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth | Molecular Cancer Therapeutics | 2011 | 1,062 |
| 6 | Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts | Molecular Cancer Therapeutics | 2004 | 1,040 |
| 7 | The Role of Autophagy in Cancer: Therapeutic Implications | Molecular Cancer Therapeutics | 2011 | 1,018 |
| 8 | MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted DrugsIn vitroandIn vivo | Molecular Cancer Therapeutics | 2010 | 821 |
| 9 | Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts | Molecular Cancer Therapeutics | 2004 | 812 |
| 10 | Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer | Molecular Cancer Therapeutics | 2014 | 774 |
| 11 | Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery | Molecular Cancer Therapeutics | 2006 | 701 |
| 12 | The role of the cyclin-dependent kinase inhibitor p21 in apoptosis | Molecular Cancer Therapeutics | 2002 | 676 |
| 13 | Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib | Molecular Cancer Therapeutics | 2014 | 627 |
| 14 | Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma | Molecular Cancer Therapeutics | 2007 | 612 |
| 15 | Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells | Molecular Cancer Therapeutics | 2006 | 607 |
| 16 | Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin | Molecular Cancer Therapeutics | 2008 | 580 |
| 17 | The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo | Molecular Cancer Therapeutics | 2001 | 552 |
| 18 | Tumor-stroma interactions in pancreatic ductal adenocarcinoma | Molecular Cancer Therapeutics | 2007 | 539 |
| 19 | DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation | Molecular Cancer Therapeutics | 2009 | 518 |
| 20 | Platinum neurotoxicity pharmacogenetics | Molecular Cancer Therapeutics | 2009 | 500 |
| 21 | A modeling analysis of the effects of molecular size and binding affinity on tumor targeting | Molecular Cancer Therapeutics | 2009 | 497 |
| 22 | Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity | Molecular Cancer Therapeutics | 2007 | 480 |
| 23 | Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor | Molecular Cancer Therapeutics | 2012 | 480 |
| 24 | Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells | Molecular Cancer Therapeutics | 2002 | 472 |
| 25 | Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells | Molecular Cancer Therapeutics | 2005 | 461 |
| 26 | Marine natural products as anticancer drugs | Molecular Cancer Therapeutics | 2005 | 459 |
| 27 | Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma | Molecular Cancer Therapeutics | 2014 | 457 |
| 28 | Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor | Molecular Cancer Therapeutics | 2010 | 456 |
| 29 | Discovery and development of anticancer aptamers | Molecular Cancer Therapeutics | 2006 | 449 |
| 30 | Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? | Molecular Cancer Therapeutics | 2010 | 444 |
| 31 | Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes | Molecular Cancer Therapeutics | 2018 | 444 |
| 32 | Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents | Molecular Cancer Therapeutics | 2009 | 443 |
| 33 | Antisense oligonucleotides: basic concepts and mechanisms | Molecular Cancer Therapeutics | 2002 | 441 |
| 34 | A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo | Molecular Cancer Therapeutics | 2012 | 439 |
| 35 | SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer | Molecular Cancer Therapeutics | 2003 | 438 |
| 36 | The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth | Molecular Cancer Therapeutics | 2005 | 435 |
| 37 | Epigenetics in cancer: Targeting chromatin modifications | Molecular Cancer Therapeutics | 2009 | 435 |
| 38 | Targeting Microtubules by Natural Agents for Cancer Therapy | Molecular Cancer Therapeutics | 2014 | 433 |
| 39 | Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance | Molecular Cancer Therapeutics | 2009 | 428 |
| 40 | Survivin, a cancer target with an emerging role in normal adult tissues | Molecular Cancer Therapeutics | 2006 | 420 |
| 41 | Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases | Molecular Cancer Therapeutics | 2006 | 410 |
| 42 | Molecular Biology of Bone Metastasis | Molecular Cancer Therapeutics | 2007 | 405 |
| 43 | In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy | Molecular Cancer Therapeutics | 2008 | 392 |
| 44 | Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials | Molecular Cancer Therapeutics | 2014 | 385 |
| 45 | Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines | Molecular Cancer Therapeutics | 2003 | 381 |
| 46 | AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models | Molecular Cancer Therapeutics | 2007 | 377 |
| 47 | Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells | Molecular Cancer Therapeutics | 2008 | 377 |
| 48 | Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors | Molecular Cancer Therapeutics | 2014 | 375 |
| 49 | Mutation analysis of 24 known cancer genes in the NCI-60 cell line set | Molecular Cancer Therapeutics | 2006 | 374 |
| 50 | BRAFV600E: Implications for Carcinogenesis and Molecular Therapy | Molecular Cancer Therapeutics | 2011 | 373 |
